⌕
Viridian Therapeutics · VRDN · Nasdaq
Tenet 42 · Weak
Compare
$30.87+1.28%At closeTenet 42 · Weak
$30.87+0.39 (+1.28%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Viridian Therapeutics (VRDN) Stock

Viridian Therapeutics (VRDN) closed at $30.87 on Nov 13, 2026; its Tenet Score is 42 of 100 against 407 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

23 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$30.87
Nov 13, 2026
Market cap
$3.5B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
13.18 – 34.29
low → high
Tenet Score
42/100
Weak · 407 Healthcare peers

Industry: Health Services · see every company filed here →

Viridian Therapeutics Inc scores 42/100. Weak. Strongest on financial health, quality is the soft spot versus 407 Healthcare peers.

Tenet Score · vs sector

n=407
42/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
25
Quality
19
Health
70
Growth
55

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityFHealthBGrowthCMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
loss
P/B
7.3×
price to book value
P/S
133.2×
price to fiscal 2025 sales
ROE
−114%
return on equity
Operating margin
−512.9%
fiscal 2025, before interest and tax
Net margin
−1724.1%
of revenue kept
Current ratio
14.46
current assets to liabilities
Net debt / EBITDA
—
no_ebitda
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Viridian Therapeutics Inc

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye di…

Composite computed Nov 15, 2026 · peer basis: Healthcare (n=407) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 75 US ETFs · top wrappers by weightSee all ETFs holding VRDN →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Viridian Therapeutics in?

Viridian Therapeutics is in the Healthcare sector and the Health Services industry.

What is Viridian Therapeutics' Tenet Score?

Viridian Therapeutics' Tenet Score is 42 out of 100, ranked against 407 Healthcare peers as of Nov 15, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.